William McGowan

Executive Director, Finance And Fp&a at SalioGen Therapeutics

William McGowan has over two decades of work experience in the finance and accounting field. William began their career as a Cost Accountant at AVX in 1997, followed by a position as a Staff Accountant at Alemite Corp in 1999. In 2000, they moved to CCL Label, where they held roles as Controller and Manager of Strategic Analysis. In 2006, they became a Leader- Financial Planning and Analysis at Danaher. In 2007, they were hired as Director, Financial Planning & Analysis at AMAG Pharmaceuticals, Inc. In 2016, they were hired as Senior Director of Finance, Controller at Navitor Pharmaceuticals. In 2021, they were hired as Senior Director, FP&A at Allena Pharmaceuticals, Inc. and most recently, in 2022, they were hired as Executive Director, Finance and FP&A at SalioGen Therapeutics.

William McGowan obtained their MBA in Finance from Quinnipiac University - School of Business between 2004 and 2006. William also obtained a B.S. in Accounting from the Darla Moore School of Business in 1998-1999 and a B.S. in Finance from the same institution between 1993 and 1997. In October 2000, they were certified as a Management Accountant by the IMA | Institute of Management Accountants.

Location

Arlington, United States

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices


SalioGen Therapeutics

1 followers

SalioGen Therapeutics is advancing the Exact DNA Integration Technology (EDIT) platform, the only genome engineering technology that is mammal-derived, for use in potentially curative non-viral gene therapy.


Employees

51-200

Links